Clinical & Pharma

Kidney disease patients rely on numerous pharmaceuticals—including erythropoiesis-stimulating agents (ESAs),iron, Vitamin D, phosphate binders and calcium—to ensure proper care. In addition, new clinical research is released on a regular basis by nephrologists and other doctors to advance the field of nephrology.

WASHINGTON—Complex socioeconomic and residential factors may account for differences in survival between Black and White kidney failure patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings ...More

SAN FRANCISCO—Many people who suffer from chronic kidney disease (CKD) progressively lose their kidney function over time and eventually develop a condition called end-stage renal disease (ESRD) — the complete failure of the kidneys—placing them in need of lifelong dialysis ...More

THOUSAND OAKS, Calif.—Amgen announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. Over the next several years, Amgen anticipates investing approximately $200 million to build an innovative new facility, which will initially ...More

ST. LOUIS—In a research review article published in the American Journal of Nephrology, Saint Louis University investigators examined data from multiple studies to better understand how obesity, an epidemic in the U.S., impacts kidney transplant patients. The authors report ...More

WASHINGTON—A drug that protects the kidneys of patients with chronic kidney disease (CKD) does not seem to provide the same benefit to kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology ...More

PHOENIX—The Alport Syndrome Foundation, Inc. (ASF) and the Kidney Foundation of Canada (KFOC) are pleased to announce the availability of funding for basic science and clinical research on the natural history, biochemical basis, and treatment of Alport Syndrome. There are ...More

MONTREL, Canada—Patients who take a triple combination of blood pressure drugs and common painkillers are at an increased risk of serious kidney problems, especially at the start of treatment, finds a study published on bmj.com. ...More

WIXOM, Mich.—Rockwell Medical announced that patient dosing has completed in its PRIME clinical study, which is designed to investigate the reduction in the need for erythropoiesis stimulating agents (ESAs) in hemodialysis patients receiving Soluble Ferric Pyrophosphate ...More

PALO ALTO, Calif. & DEERFIELD, Ill.—Affymax and Takeda Pharmaceuticals U.S.A. (TPUSA) announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for Omontys (peginesatide) Injection is now effective. This permanent Omontys-specific ...More